Phase 2Active, not recruiting
A Study to Compare Different Doses of RO7795081 With Placebo or Semaglutide in People With Type 2 Diabetes
A Randomized, Double-Blind, Placebo- and Open-Label Active Comparator- Controlled, Parallel-Group, Multi-Center Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Daily RO7795081 Administered for 30 Weeks to Participants With Type 2 Diabetes Mellitus
- Sponsor
- Hoffmann-La Roche (Industry)
- Enrolment
- 330 planned
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- RO7795081; Semaglutide; Placebo
- Ages
- adults, older adults
- Registry
- NCT07112872
From the registry
This multicenter, randomized, double-blind, placebo- and open-label active comparator-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of different doses of RO7795081 for glycemic control in adult participants with Type 2 diabetes mellitus (T2D).
Primary outcomes
- RO7795081 vs. Placebo: Change in Glycated Hemoglobin (HbA1c) from Baseline at Week 30
In the news
Randomized trial investigates kidney protective mechanisms of semaglutide in type 2 diabetes
Researchers examined semaglutide in type 2 diabetes patients using histology, multiparametric MRI, and transcriptomics to understand renal protection.